ざわざわざーわざわ
reacted to
7
ざわざわざーわざわ
liked
$Hims & Hers Health (HIMS.US)$
The stock price has fallen by 17% in after-hours Trade, causing a state of panic.
But wait a minute...
- 20% of the revenue for fiscal year 2024 is due to semaglutide.
- The company has removed this from its guidance starting from the first quarter of fiscal year 2025.
- Even so... the full-year guidance was raised by 56%.
💡
The stock price has fallen by 17% in after-hours Trade, causing a state of panic.
But wait a minute...
- 20% of the revenue for fiscal year 2024 is due to semaglutide.
- The company has removed this from its guidance starting from the first quarter of fiscal year 2025.
- Even so... the full-year guidance was raised by 56%.
💡
Translated
18
1
ざわざわざーわざわ
liked
$Hims & Hers Health (HIMS.US)$
$HIMS has been providing a complex GLP-1 injection (compounded medication) on its own platform in the field of weight management against the backdrop of a shortage of GLP-1 drugs. This has significantly contributed to growth in 2024 (revenue up 95%, number of subscribers up 45%), as revealed in the earnings report. However, concerns arise when the shortage is resolved:
– If Novo-Nordisk A/S brand drugs (OZEMPIC, WEGOVY, Victoza, etc.) become sufficiently available in the market, patients may choose the genuine products over compounded medications.
– In America, the provision of compounded medications is recognized by FDA regulations as a temporary measure during supply shortages, so legal constraints could arise when the shortage is resolved.
Management's perspective and response strategies.
From the management's comments during the Q4 2024 earnings conference Call, $HIMS has prepared a strategy to anticipate this situation:
– Continuation of combination GLP-1.: CEO Andrew Doughty emphasized, "Even if supply shortages are resolved, the demand for combination GLP-1, which has cost and access advantages, will remain." $HIMS's compounded medications are significantly lower priced than branded drugs (for example...
$HIMS has been providing a complex GLP-1 injection (compounded medication) on its own platform in the field of weight management against the backdrop of a shortage of GLP-1 drugs. This has significantly contributed to growth in 2024 (revenue up 95%, number of subscribers up 45%), as revealed in the earnings report. However, concerns arise when the shortage is resolved:
– If Novo-Nordisk A/S brand drugs (OZEMPIC, WEGOVY, Victoza, etc.) become sufficiently available in the market, patients may choose the genuine products over compounded medications.
– In America, the provision of compounded medications is recognized by FDA regulations as a temporary measure during supply shortages, so legal constraints could arise when the shortage is resolved.
Management's perspective and response strategies.
From the management's comments during the Q4 2024 earnings conference Call, $HIMS has prepared a strategy to anticipate this situation:
– Continuation of combination GLP-1.: CEO Andrew Doughty emphasized, "Even if supply shortages are resolved, the demand for combination GLP-1, which has cost and access advantages, will remain." $HIMS's compounded medications are significantly lower priced than branded drugs (for example...
Translated
15
ざわざわざーわざわ
liked
$Super Micro Computer (SMCI.US)$
It's difficult to determine with the current price being maintained. It's a dilemma whether to step out for a while or hold until the deadline on 2/25 (that was a typo for 5/25. No need to get involved in every little detail).
If it keeps rising, holding is a good decision, but if there is a downward trend, it is wise to exit temporarily and re-enter.
Decide based on today's atmosphere. Individual short-term decisions should prioritize the atmosphere.
It's difficult to determine with the current price being maintained. It's a dilemma whether to step out for a while or hold until the deadline on 2/25 (that was a typo for 5/25. No need to get involved in every little detail).
If it keeps rising, holding is a good decision, but if there is a downward trend, it is wise to exit temporarily and re-enter.
Decide based on today's atmosphere. Individual short-term decisions should prioritize the atmosphere.
Translated
11
6
ざわざわざーわざわ
liked
Translated
6
ざわざわざーわざわ
reacted to
$Super Micro Computer (SMCI.US)$
Are we experiencing another delay?
Don't be joking.![]()
![]()
![]()
Is there an explanation and apology press conference starting from 7 o'clock?![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
Are we experiencing another delay?
Don't be joking.
Is there an explanation and apology press conference starting from 7 o'clock?
Translated
7
ざわざわざーわざわ
liked
$Super Micro Computer (SMCI.US)$
The game is over when Hindenburg Research, the very one who unjustifiably accused and caused the stock price to collapse, went out of business. If there are no parties involved, who is the report for? Besides, NASDAQ did not request a re-investigation of SMCI, as there were suspicions.
Seeing the stock price skyrocket makes it clear that trust has been restored. And it will continue in the future.![]()
The game is over when Hindenburg Research, the very one who unjustifiably accused and caused the stock price to collapse, went out of business. If there are no parties involved, who is the report for? Besides, NASDAQ did not request a re-investigation of SMCI, as there were suspicions.
Seeing the stock price skyrocket makes it clear that trust has been restored. And it will continue in the future.
Translated
25
1
ざわざわざーわざわ
liked and commented on
Go for it SMCI‼️ It's not a low-level discussion about continuing on the Nasdaq level.![]()
Translated
13
3
ざわざわざーわざわ
liked
Translated
8
ざわざわざーわざわ
liked
$Super Micro Computer (SMCI.US)$
Stock has been prepared again. The system for increasing production is fully in place.![]()
Stock has been prepared again. The system for increasing production is fully in place.
Translated
6